Clinical Efficacy and Safety Observation of Apatinib Combined with Carolizumab in the Treatment of Advanced Liver Cancer
Objective:To explore the clinical efficacy and safety of Apatinib combined with Carolizumab in the treatment of advanced liver cancer.Method:Sixty patients diagnosed with advanced hepatocellular carcinoma(HCC)admitted to Tongzhou District People's Hospital of Nantong City from March 2020 to March 2023 were selected as the study objects.The patients were divided into study group and control group,with 30 cases in each group.For the study group and the control group,Carolizumab combined with Apatinib treatment and apatinib monotherapy treatment were respectively given,and the adverse reactions,clinical efficacy and progression-free survival time of the two groups after treatment were compared.Result:After 6 weeks of treatment,the ORR and DCR of the study group were higher than those of the control group,and the differences were statistically significant(P<0.05).The median DFS in the control group was 4.2 months,while the median DFS in the study group was 6.8 months.The median DFS of the study group was higher than that of control group,with a statistical significance(P<0.05).Conclusion:The combination of Apatinib and Carolizumab has better short-term clinical efficacy compared to the single use of Apatinib,with greater survival benefits for patients and no increase in adverse reactions after medication.
万方数据
维普
